Abstract
Improving the evidence base for trauma care: progress in the international CRASH-2 trial.
Highlights
Background to the TrialBetween the ages of 5 and 45 years, trauma is second only to HIV/AIDS as a cause of death
Among trauma patients who do survive to reach hospital, excessive blood loss is a common cause of death, accounting for nearly half of in-hospital trauma deaths [2]
A World Health Organization study compared the level of research funding with current and projected (2020) disease burden
Summary
Improving the Evidence Base for Trauma Care: Progress in the International CRASH-2 Trial. There is an urgent need to improve the evidence base for trauma care. The CRASH-2 trial, which is currently under way (registered at ISRCTN86750102), is a large placebocontrolled trial being performed in trauma patients at risk of significant haemorrhage. The trial examines the effects of antifibrinolytic treatment on death and the need for blood transfusion. If such a simple and widely practicable treatment as the antifibrinolytic agent tranexamic acid (TXA) were shown to reduce blood loss after trauma, thousands of trauma deaths could be preventable worldwide. We present an overview of the progress of the trial and urge physicians working in emergency care to consider joining this international collaborative effort
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
